BR112016019837A2 - plasmídeos imunoestimuladores - Google Patents
plasmídeos imunoestimuladoresInfo
- Publication number
- BR112016019837A2 BR112016019837A2 BR112016019837A BR112016019837A BR112016019837A2 BR 112016019837 A2 BR112016019837 A2 BR 112016019837A2 BR 112016019837 A BR112016019837 A BR 112016019837A BR 112016019837 A BR112016019837 A BR 112016019837A BR 112016019837 A2 BR112016019837 A2 BR 112016019837A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunostimulatory plasmids
- methods
- dna sequences
- antibiotic resistance
- plasmids
- Prior art date
Links
- 230000003308 immunostimulating effect Effects 0.000 title abstract 3
- 239000013612 plasmid Substances 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16771—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946372P | 2014-02-28 | 2014-02-28 | |
| PCT/EP2015/054131 WO2015128461A1 (en) | 2014-02-28 | 2015-02-27 | Immunostimulatory plasmids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016019837A2 true BR112016019837A2 (pt) | 2017-10-17 |
Family
ID=52598746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016019837A BR112016019837A2 (pt) | 2014-02-28 | 2015-02-27 | plasmídeos imunoestimuladores |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10155950B2 (https=) |
| EP (1) | EP3110940A1 (https=) |
| JP (1) | JP6772065B2 (https=) |
| KR (1) | KR20160122849A (https=) |
| CN (1) | CN106029867B (https=) |
| AU (1) | AU2015222102B2 (https=) |
| BR (1) | BR112016019837A2 (https=) |
| CA (1) | CA2940794C (https=) |
| CL (1) | CL2016002146A1 (https=) |
| CR (1) | CR20160393A (https=) |
| DO (1) | DOP2016000223A (https=) |
| IL (1) | IL247065A0 (https=) |
| MX (1) | MX2016010993A (https=) |
| PE (1) | PE20170404A1 (https=) |
| PH (1) | PH12016501705A1 (https=) |
| RU (1) | RU2740492C2 (https=) |
| SV (1) | SV2016005263A (https=) |
| UA (1) | UA118374C2 (https=) |
| WO (1) | WO2015128461A1 (https=) |
| ZA (1) | ZA201605495B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160122849A (ko) * | 2014-02-28 | 2016-10-24 | 바이엘 애니멀 헬스 게엠베하 | 면역자극성 플라스미드 |
| TR201908550T4 (tr) | 2014-06-04 | 2019-07-22 | Exicure Inc | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. |
| US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| KR20180021874A (ko) * | 2015-06-26 | 2018-03-05 | 바이엘 애니멀 헬스 게엠베하 | 시토졸 dna 감시 분자의 조절 방법 |
| SG10202000891UA (en) * | 2015-07-31 | 2020-03-30 | Bayer Animal Health Gmbh | Enhanced immune response in porcine species |
| EP3328423B1 (en) * | 2015-07-31 | 2021-05-26 | Bayer Animal Health GmbH | Enhanced immune response in fish |
| TWI759317B (zh) * | 2016-07-26 | 2022-04-01 | 德商拜耳動物保健有限公司 | 牛物種中增加的生育力 |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| CR20200260A (es) * | 2017-12-15 | 2020-08-01 | Bayer Animal Health Gmbh | Composiciones inmunoestimulantes |
| CN109646435B (zh) * | 2019-01-11 | 2021-08-03 | 山东省农业科学院奶牛研究中心 | 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5427791A (en) | 1992-08-05 | 1995-06-27 | Regents Of The University Of Minnesota | Embryonal vaccine against Newcastle disease |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
| US5830878A (en) | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6048535A (en) | 1997-06-12 | 2000-04-11 | Regents Of The University Of Minnesota | Multivalent in ovo avian vaccine |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| ATE397942T1 (de) | 1999-03-26 | 2008-07-15 | Vical Inc | Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen |
| US20040002472A1 (en) | 2000-01-21 | 2004-01-01 | Audonnet Jean-Christophe Francis | Vaccination or immunization using a prime-boost regimen |
| US6517218B2 (en) | 2000-03-31 | 2003-02-11 | Relume Corporation | LED integrated heat sink |
| CN1636050A (zh) * | 2001-04-24 | 2005-07-06 | 基因创新有限公司 | 核心糖基化hcv包膜蛋白 |
| WO2003004051A2 (en) | 2001-07-02 | 2003-01-16 | Pfizer Products Inc. | Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
| AU2002953015A0 (en) * | 2002-12-02 | 2002-12-12 | Women's And Children's Hospital | Modified lacz gene |
| CN1764474B (zh) | 2003-03-26 | 2011-02-02 | 惠氏公司 | 免疫原性组合物及方法 |
| CA2542099A1 (en) | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| US20050181035A1 (en) | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
| WO2006017857A2 (en) | 2004-08-13 | 2006-02-16 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free dna vaccines |
| US20090068223A1 (en) | 2005-11-15 | 2009-03-12 | Boehringer Ingelheim Vetmedica, Inc. | Combination vaccine comprising an attenuated bovine viral diarrhea virus |
| TWM297441U (en) | 2006-03-30 | 2006-09-11 | Cheng-Jiun Jian | LED projection light source module |
| US7663229B2 (en) | 2006-07-12 | 2010-02-16 | Hong Kong Applied Science And Technology Research Institute Co., Ltd. | Lighting device |
| US20090275642A1 (en) * | 2006-10-06 | 2009-11-05 | Reisfeld Ralph A | Dna composition for eliciting an immune response against tumor-associated macrophages |
| WO2009046388A1 (en) * | 2007-10-03 | 2009-04-09 | United States Medical Research & Material Command | Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines |
| EP2257306B1 (en) | 2008-03-25 | 2014-05-07 | Juvaris Biotherapeutics, Inc. | Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc) |
| MX2011004316A (es) | 2008-10-31 | 2011-06-16 | Boehringer Ingelheim Vetmed | Uso de antigenos diversos que incluyen antigenos de mycoplasma bovis en composicion de vacuna multivalente. |
| WO2010130374A1 (en) * | 2009-05-14 | 2010-11-18 | Bayer Animal Health Gmbh | Enhanced immune response in avian species |
| BR112013016231B1 (pt) | 2010-12-22 | 2021-03-23 | Bayer Intellectual Property Gmbh | Composição imunomoduladora para o tratamento de doença respiratória bovina |
| CL2011000065A1 (es) | 2011-01-11 | 2011-04-15 | Univ Concepcion | Formulacion veterinaria para la prevencion y eliminacion de infeccion por cepas de e. coli stec, que comprende un plasmido recombinante que codifica un factor de virulencia y liposoma cationico como vehiculo, uso de dicha formulacion para tratar preferentemente bovinos y porcinos. |
| KR20160122849A (ko) * | 2014-02-28 | 2016-10-24 | 바이엘 애니멀 헬스 게엠베하 | 면역자극성 플라스미드 |
-
2015
- 2015-02-27 KR KR1020167026797A patent/KR20160122849A/ko not_active Withdrawn
- 2015-02-27 US US14/633,920 patent/US10155950B2/en active Active
- 2015-02-27 AU AU2015222102A patent/AU2015222102B2/en not_active Ceased
- 2015-02-27 CN CN201580010413.0A patent/CN106029867B/zh not_active Expired - Fee Related
- 2015-02-27 RU RU2016138321A patent/RU2740492C2/ru active
- 2015-02-27 CR CR20160393A patent/CR20160393A/es unknown
- 2015-02-27 CA CA2940794A patent/CA2940794C/en active Active
- 2015-02-27 MX MX2016010993A patent/MX2016010993A/es unknown
- 2015-02-27 PE PE2016001534A patent/PE20170404A1/es not_active Application Discontinuation
- 2015-02-27 WO PCT/EP2015/054131 patent/WO2015128461A1/en not_active Ceased
- 2015-02-27 BR BR112016019837A patent/BR112016019837A2/pt not_active Application Discontinuation
- 2015-02-27 EP EP15707606.8A patent/EP3110940A1/en not_active Ceased
- 2015-02-27 JP JP2016554261A patent/JP6772065B2/ja not_active Expired - Fee Related
- 2015-02-27 UA UAA201609729A patent/UA118374C2/uk unknown
-
2016
- 2016-08-02 IL IL247065A patent/IL247065A0/en unknown
- 2016-08-08 ZA ZA2016/05495A patent/ZA201605495B/en unknown
- 2016-08-24 CL CL2016002146A patent/CL2016002146A1/es unknown
- 2016-08-26 DO DO2016000223A patent/DOP2016000223A/es unknown
- 2016-08-26 PH PH12016501705A patent/PH12016501705A1/en unknown
- 2016-08-26 SV SV2016005263A patent/SV2016005263A/es unknown
-
2018
- 2018-04-25 US US15/962,414 patent/US10851379B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2940794A1 (en) | 2015-09-03 |
| JP2017512202A (ja) | 2017-05-18 |
| ZA201605495B (en) | 2022-08-31 |
| US20180312842A1 (en) | 2018-11-01 |
| US20150267201A1 (en) | 2015-09-24 |
| US10851379B2 (en) | 2020-12-01 |
| DOP2016000223A (es) | 2016-09-30 |
| JP6772065B2 (ja) | 2020-10-21 |
| CN106029867A (zh) | 2016-10-12 |
| PE20170404A1 (es) | 2017-05-14 |
| RU2740492C2 (ru) | 2021-01-14 |
| RU2016138321A (ru) | 2018-03-30 |
| KR20160122849A (ko) | 2016-10-24 |
| AU2015222102A1 (en) | 2016-08-18 |
| UA118374C2 (uk) | 2019-01-10 |
| CR20160393A (es) | 2017-12-14 |
| MX2016010993A (es) | 2017-05-01 |
| IL247065A0 (en) | 2016-09-29 |
| CL2016002146A1 (es) | 2017-08-04 |
| SV2016005263A (es) | 2018-01-16 |
| RU2016138321A3 (https=) | 2018-11-12 |
| EP3110940A1 (en) | 2017-01-04 |
| PH12016501705A1 (en) | 2016-10-03 |
| WO2015128461A1 (en) | 2015-09-03 |
| US10155950B2 (en) | 2018-12-18 |
| CA2940794C (en) | 2022-05-31 |
| CN106029867B (zh) | 2020-02-14 |
| AU2015222102B2 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016019837A2 (pt) | plasmídeos imunoestimuladores | |
| CY1123823T1 (el) | Βελτιωμενες συνθεσεις τ κυτταρων | |
| CY1124004T1 (el) | Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους | |
| ME03463B (me) | Kompozicije koje sadrže bakterijske sojeve | |
| ME03511B (me) | Kompozicije koje sadrže bakterijske sojeve | |
| LT3307288T (lt) | Kompozicijos, apimančios bakterijų kamienus | |
| MX2017006695A (es) | Variantes de subtilasa y polinucleotidos que las codifican. | |
| CY1119093T1 (el) | Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο | |
| CN106715699A8 (zh) | 用于减弱抗病毒转移载体免疫应答的方法和组合物 | |
| IL250388A0 (en) | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells | |
| MX2017014469A (es) | Constructos de expresion y metodos para diseñar geneticamente levadura metilotrofica. | |
| DK3377082T3 (da) | Sammensætninger, der omfatter bakteriestammer | |
| PH12016500165A1 (en) | Compositions and methods related to isolated endophytes | |
| PL3549592T3 (pl) | Kompozycje zawierające szczepy bakteryjne | |
| ME03562B (me) | Kompozicije koje sadrže bakterijske sojeve | |
| MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
| IL247469A0 (en) | Methods for refining conjugates based on alpha il-15/il-15r, preparations containing products produced in this way and their uses | |
| MX344972B (es) | Oligonucleotidos inmunoestimulantes. | |
| MY181175A (en) | Therapeutic hpv16 vaccines | |
| EP4480544A3 (en) | Immunomodulatory compositions andmethods of use thereof | |
| MX2017016401A (es) | Composiciones inmunogenas. | |
| PH12014502855B1 (en) | Attenuated streptococcus suis vaccines and methods of making and use thereof | |
| EA201692025A1 (ru) | Доставка белков, осуществляемая на основе бактерий | |
| MX378857B (es) | Celulas huespedes modificadas y usos de las mismas. | |
| ZA201603187B (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |
|
| B25H | Request for change of headquarter rejected |
Owner name: BAYER ANIMAL HEALTH GMBH (DE) Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 870240023600 DE 19/03/2024 DEVIDO AO DESPACHO PUBLICADO NA RPI 2790 DE 25/06/2024. |
|
| B25E | Requested change of name of applicant rejected |
Owner name: BAYER ANIMAL HEALTH GMBH (DE) Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 870240023600 DE 19/03/2024 DEVIDO AO DESPACHO PUBLICADO NA RPI 2790 DE 25/06/2024. |